Dash Bio Secures $11M to Accelerate a New Era in Bioanalysis
NEWTON, Mass., July 23, 2025 /PRNewswire/ — Dash Bio, a preclinical and clinical bioanalysis company reinventing the speed and scalability of drug development, today announced it has raised an additional $11 million in funding, bringing its total raised to $17.5 million. The new financing was led by The Aligned Fund, with participation from Freestyle Capital, Cybernetix Ventures, Swift Ventures, LifeX Ventures, Drive Capital, and others.
Dash Bio's mission is bold but urgent: to rebuild drug development for a modern biotech era. While drug discovery has seen massive innovation through AI, mRNA, and CRISPR, drug development — the 7–12 year, multi-billion-dollar black hole between discovery and approval — remains stuck in a slow, expensive, and highly manual past. Over 70% of development work is outsourced to CROs whose labor-intensive service models are misaligned with the industry's need for speed.
Dash Bio is tackling this bottleneck head-on. The company has built the first highly automated, GLP-compliant bioanalysis lab purpose-built to eliminate the friction of traditional CROs. Dash delivers assays like ELISA, LC-MS, and qPCR at speeds up to 10x faster than current providers — helping drug developers move from idea to IND to approval faster than ever before.
'We founded Dash because the broken state of development is one of the biggest threats to progress in biotech,' said Dave Johnson, co-founder and CEO of Dash Bio and former Chief Data & AI Officer at Moderna. 'Our platform was designed the right way from day one: real automation, real integration, and real science. This funding is a strong signal that the industry is ready to embrace a new standard — one where bioanalysis is a catalyst, not a constraint.'
The company's approach is resonating. Since its initial raise, Dash has added top-tier biopharma companies as customers and assembled a powerhouse team including former colleagues from Moderna, Science Exchange, Rootpath, and other trailblazers. With deep expertise in bioanalysis, software engineering, and lab automation, the team is uniquely positioned to bring industrial-grade efficiency to drug development.
'Dash Bio isn't just faster — it's foundational,' said Ariel Winton-Jones, Partner at The Aligned Fund. 'Their team has built the kind of tech-forward infrastructure that biotech has needed for years. We believe Dash is creating the modern stack for bioanalysis and beyond.'
With this funding, Dash Bio will continue scaling its automated platform, expanding its assay menu, investing in its proprietary sample and assay management software, and onboarding new customers from preclinical through late-stage clinical development.
About Dash BioDash Bio accelerates clinical development by delivering high-quality, technology-driven bioanalysis at unprecedented speed. Its fully automated, GLP-compliant lab platform combines robotics, AI, and integrated software to deliver faster results and better data — helping biopharma teams get therapies to patients faster. Learn more at www.dash.bio.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
a day ago
- The Sun
AEON Bank and foodpanda Embark on a Strategic Partnership to Drive Growth and Create Value for Customers, Riders and Merchants
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 1 August 2025 - AEON Bank (M) Berhad, Malaysia's first Islamic digital bank has officially entered into a strategic partnership with foodpanda Malaysia, the country's leading online food and grocery delivery platform. This business-to-business (B2B) collaboration aims to increase digital banking adoption among their combined stakeholders and empower Malaysia's gig economy through innovative fintech solutions, while simultaneously promoting financial inclusion. The Memorandum of Understanding (MoU) between AEON Bank and foodpanda Malaysia outlines a broad scope of collaboration, including customer acquisition, digital financing, joint campaigns and value-added services for their wider ecosystem of customers, riders, merchants and business partners. YM Raja Datin Paduka Teh Maimunah Raja Abdul Aziz, Chief Executive Officer of AEON Bank stated, 'This strategic partnership with foodpanda marks the beginning of an exciting chapter for AEON Bank. We look forward to providing value to foodpanda riders and merchants by enabling access to digital banking, rewards programmes and services that elevate their experience. By optimising foodpanda's expansive network and connecting it with AEON Bank's Shariah-compliant products and AEON Points loyalty programme, we aim to deliver meaningful impacts to the target segments — particularly gig workers and MSMEs — while driving growth and engagement.' This partnership is strategically positioned to contribute to Malaysia's rapidly growing food delivery and online grocery sector, where user penetration is expected to reach 34.2% in 2025 and over 14.5 million users by 2030 . 'We are thrilled to join forces with AEON Bank to create real, tangible benefits for everyone in the foodpanda community. For our riders, this partnership goes beyond deliveries — it enables access to tech-driven financial support, microfinancing and financial literacy programmes that can improve their livelihoods. Meanwhile, our merchant partners will have greater opportunities to grow their businesses faster with targeted campaigns and financing solutions to scale their operations. And for our customers, they can expect more value and convenience with exclusive rewards and easier access to AEON's retail ecosystem. This partnership is more than just a commercial collaboration — it's about empowering riders, accelerating merchant growth and making every customer experience even more rewarding,' said Tan Ming Luk, Managing Director of foodpanda Malaysia. Various key programmes will be introduced as part of this collaboration, including co-branding engagement featuring the two mascots; AEON Bank's Neko and foodpanda's Pau-Pau. Several initiatives currently in the pipeline are: For Riders • A joint programme to support delivery riders in enhancing their mobility and livelihood, including access to AEON Bank's digital banking offering, financial tools and essential work resources, such as microfinancing for devices and motorcycle purchases • Financial literacy initiative to expand outreach and financial empowerment among the riders For Merchant Partners • Targeted campaigns with AEON Bank for foodpanda's merchants • Financial solutions for merchants through the AEON Bank to Business (AB2B) Programme and financing for wholesale purchases, enabling inventory expansion and business growth For Customers • Special rewards and promotions for customers, while adding value to their foodpanda orders • Expanded access across the AEON retail ecosystem, hence allowing customers to purchase groceries online beyond just AEON MaxValu Prime, thereby increasing convenience. This alliance between AEON Bank and foodpanda Malaysia highlights a shared commitment towards improving the financial well being of the thriving community, driving innovation and supporting Malaysia's socioeconomic development through digital inclusion. Both brands will leverage each other's strength, aligned with a strategic mission to provide value based, customer-centric digital financial solutions that will deliver dynamic growth. Visit the website of AEON Bank and foodpanda for further details and stay updated on exclusive offers on social media.
The Sun
a day ago
- The Sun
Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland
HONG KONG SAR - Media OutReach Newswire - 1 August 2025 - Cushman & Wakefield, a leading global real estate services firm, today released its Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland report. It is based on in-depth interview surveys we conducted on professionals active in the life sciences sector on the Chinese mainland. The life sciences industry on the Chinese mainland is undergoing a transformative phase, driven by progressive policies, groundbreaking innovations, the emergence of influential life sciences companies, and strategic regional development. This report delves into the latest trends shaping the sector. Policy Landscape – National and Local Catalysts Reforms enacted in 2024-2025 have significantly accelerated sector development. Nationally, China relaxed restrictions on foreign investment in gene and cell therapy and allowed the establishment of wholly foreign-owned hospitals in key cities. Regulatory incentives – such as data protection and marketing exclusivity – have improved market access for innovative drugs. Locally, cities like Beijing, Shanghai, Shenzhen, Guangzhou, and Suzhou are rolling out targeted subsidies, fast-track approvals, and ecosystem-building programmes that directly benefit biotech development. Recent national policy initiatives on the Chinese mainland Industry Innovation and Company Growth Chinese life sciences companies are moving beyond generic drug manufacturing toward innovative therapies. Firms like Akeso, BeiGene, Gracell, and Legend Biotech are now global players, leading in CAR-T, bispecific antibodies, and AI-assisted R&D. These companies are not only commercialising cutting-edge treatments but also attracting international investment and licensing agreements, reinforcing the Chinese mainland's global relevance in life sciences. Real Estate Development and Regional Hubs Innovation hubs such as Suzhou BioBAY, Zhangjiang Hi-Tech Park (Shanghai), and the Bioisland Innovation Centre (Guangdong) are central to regional clustering. These hubs offer end-to-end support, including shared labs, venture capital access, GMP-compliant facilities, and proximity to academic and clinical networks. The rise of second-tier innovation cities like Chengdu and Ningbo further expands growth corridors. The 'R&D + Manufacturing + Service' ecosystem Source: Cushman & Wakefield Research Landlord Perspectives – Evolving Real Estate Models Real estate developers and landlords are adapting to sector-specific requirements through asset-light models, flexible leasing, and high-specification lab and production space. Tier-1 cities face saturation, but central and western regions exhibit healthy demand. Developers are incorporating advanced sustainability and compliance features to meet growing regulatory and ESG expectations, particularly in GMP and cleanroom environments. Digitalisation, environmental policies, and differentiated tenant strategies are shaping performance. Operators now focus on integrated ecosystems with platforms that link tenants to R&D services, policy benefits, and technology partners. Occupier Perspectives – Growth, Innovation, and Challenges Life sciences occupiers are navigating regulatory reform, rising compliance demands, and intensified market competition. Many are localising production and R&D, leveraging regional subsidies, and investing in AI-powered innovation platforms. Occupiers seek flexibility, proximity to talent and infrastructure, and co-located R&D and manufacturing to support accelerated innovation and operational agility. In real estate, demand is strongest for GMP-certified labs, modular production facilities, and shared innovation platforms. Occupiers emphasise location advantages, sustainability certifications (e.g., LEED, WELL), and integration into clusters that enable faster time-to-market. Tony Su, Managing Director, National Head of Industrial & Logistics Property Services, China, said, 'Life sciences business parks on the Chinese mainland demonstrated clear regional differentiation, highlighting opportunities for strategic positioning. While Tier-1 cities saw more moderate performance due to broader macroeconomic factors and abundant supply, core cities in central and western regions recorded healthy occupancy rates, underpinned by strong industrial clustering and increasingly sophisticated ecosystems – contributing to steady growth in asset value.' Johnathan Wei, President, Project & Occupier Services, China, said, 'Several interviewed life sciences companies on the Chinese mainland achieved revenue growth supported by innovative products and favourable policy tailwinds. While overall growth remained modest for many, a select group reported strong performance, highlighting opportunities for differentiation'. Andrew Chan, Managing Director, Head of Valuation & Advisory Services, Greater China, said,' Looking ahead to 2025 and beyond, growth opportunities lie in AI-driven drug discovery, personalised medicine, advanced therapeutics (CGT, RNA), and green-certified facilities. Government policies continue to support innovation through fast-track approvals, rare disease funding, and subsidies aligned with dual-carbon and ESG goals'. Shaun Brodie, Head of Research Content, Greater China, 'Life sciences real estate is shifting from generic parks to specialised, digitally enabled campuses with high compliance and flexibility. Investment strategies increasingly emphasise long-term partnerships, collaborative operating models, and digital infrastructure. Both landlords and occupiers express cautious optimism, with strategic differentiation and regional targeting seen as keys to unlocking future value'. Please click here to download the full report.
The Sun
2 days ago
- The Sun
Trump increases tariff on Canada to 35% from 25%, cites fentanyl
WASHINGTON: U.S. President Donald Trump on Thursday signed an executive order increasing tariffs on Canadian goods to 35% from 25% on all products not covered by the U.S.-Mexico-Canada trade agreement, the White House said. Goods transshipped to another country to evade the new tariffs would be subject to a transshipment levy of 40%, according to a White House fact sheet. The move - which Washington linked in part to what it said was Canada's failure to stop fentanyl smuggling - is the latest blow in a months-long tariff war which Trump initiated shortly after taking power. The announcement blaming Canada's 'continued inaction and retaliation' comes after Trump said Canadian Prime Minister Mark Carney reached out ahead of an August 1 tariff deadline, but no conversations between the two took place. Trump had said any country failing to strike a deal with the U.S. before Friday will be subjected to higher tariffs imposed on goods. Carney early on Friday said he was disappointed by Trump's decision. 'While we will continue to negotiate with the United States on our trading relationship, the Canadian government is laser focused on what we can control: building Canada strong,' Carney said in a post on X. U.S. duties and tariffs will heavily affect lumber, steel, aluminum, and automobiles, he added, vowing action to protect Canadian jobs, buy Canadian goods, invest in industrial competitiveness and diversify export markets. To justify its step, the U.S. has cited the cross-border flow of fentanyl, even though Canada accounts for just 1% of U.S. fentanyl imports and has been working intensively to further reduce the volumes, Carney added. Trump told NBC News on Thursday he was open to further discussions with Canada, adding that he may even speak with Carney later in the night. Premier Doug Ford of Ontario, which accounts for around 40% of Canadian GDP and is the country's industrial heartland, demanded Ottawa slap a 50% counter tariff on imports of U.S. steel and aluminum. 'Canada shouldn't settle for anything less than the right deal. Now is not the time to roll over. We need to stand our ground,' he said in a post on X. Trump said that while he loved Canada, it had treated the United States 'very badly' for years. U.S. Commerce Secretary Howard Lutnick said Trump could reconsider the tariff if Carney 'starts turning on the charm and if he takes off his retaliation.' Earlier Thursday, Trump agreed to give Mexico a 90-day window to work toward a deal, allowing it to avoid a 30% tariff that he threatened to impose by August 1. Mexico will still have to pay a 25% duty on U.S.-bound exports that are non USMCA-compliant, a tariff that Trump has linked to demands that Mexico do more to curb drug and human smuggling. Canada sends around 75% of all its exports south of the border and is vulnerable to U.S. trade action. The economy has shown surprising resilience in the face of tariffs and is expected to avoid recession, economists say. About 90% of Canadian exports to the U.S. in May were exempt under the USMCA. The compliance level has shot up dramatically in the last few months, while some companies have diversified exports to avoid tariffs. Canadian government data shows exports to the U.S. dropped by 10 percentage points to 68% of total exports between May 2024 and May 2025, focused on manufacturing products such as cars and parts, and products made with steel and aluminum. Carney told reporters in June that if the two countries do not reach a trade deal by August 1, Canada would likely impose more counter levies on U.S. exports of steel and aluminum. - REUTERS
